众生药业：昂拉地韦对包括H1和H3亚型的流感病毒株均能较安慰剂显著缩短流感症状缓解时间

Core Viewpoint - The company is actively advancing the commercialization of its antiviral drug, Olanidovir tablets, which shows strong efficacy against various strains of influenza, including those resistant to other treatments [2]. Group 1: Product Development - The company is progressing with the commercialization of Olanidovir tablets (brand name: Anruwei®) for the treatment of adult patients with uncomplicated influenza A [2]. - Preclinical studies indicate that Olanidovir has strong inhibitory activity against multiple influenza virus strains, including those resistant to Oseltamivir and Baloxavir [2]. - The Phase III clinical trial results comparing Olanidovir tablets with Oseltamivir capsules and placebo for treating adult influenza A have shown positive outcomes, achieving the predefined primary efficacy endpoint with good safety [2]. Group 2: Clinical Efficacy - Subgroup analysis from the Phase III trial suggests that Olanidovir significantly shortens the time to relief from influenza symptoms compared to placebo for H1 and H3 subtype strains [2].